Abstract 143P
Background
The combination of local thermal ablation with immune checkpoint inhibitors perioperatively for small hepatocellular carcinoma (HCC) is yet to be explored. The aim of this phase II trial was to evaluate the safety and tolerability of thermal ablation in combination with tislelizumab, an anti-PD-1 antibody, in patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and to make a preliminary evaluation of the efficacy of this treatment modality.
Methods
This phase II trial (NCT04652440) enrolled newly diagnosed and recurrent HCC patients with 1 or 2 lesions of 2-5 cm in size. This study included two stages. The first stage included 6 patients for dose-limited toxicity (DLT) observation. Only if DLT appeared in < 2 patients, the other 24 patients would be included. Enrolled patients received the first dose of tislelizumab intravenously within 1 day before percutaneous thermal ablation, followed by infusions every 3 weeks for totally 4 doses. The primary endpoints were safety and tolerability. Secondary endpoints included the rate of complete response by first ablation (CR1), local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates.
Results
No DLT occurred in the first 6 patients, and the study completed recruiting a total 30 subjects in July 2023. Twenty-six subjects had already finished their study treatment and were followed regularly. One patient withdrew her informed consent after completion of the ablation and the first dose of study medication. The other 3 were still on tislelizumab therapy. Until the time of data cut-off (July 30, 2023), the most common adverse events were increased alanine aminotransferase (N=15) and aspartate aminotransferase (N=19) on the first day after ablation. The majority recovered after supportive treatment. 10 patients experienced grade 1-2 immune-related adverse events (irAEs), the most common were rash (N=8), pruritus (N=5), and anorexia (N=4). No ≥3 grade irAEs occurred.
Conclusions
Thermal ablation combined with tislelizumab showed acceptable safety and tolerability with no unexpected SAEs observed. Results of efficacy will be disclosed in future.
Clinical trial identification
NCT04652440.
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract